61st Scientific Sessions of the American Diabetes Association (ADA), held June 22-24 in Philadelphia. More than 400 physicians, nurses and other healthcare professionals who visited the exhibit booth were tested for their CVProfilorä Risk Assessment during the three-day technical exhibition.

"Diabetes is striking millions today and is a major risk factor in the progression of cardiovascular disease," said Greg H. Guettler, president of Hypertension Diagnostics, Inc. (HDI). "Atherosclerosis (the formation of plaques and the accumulation of fatty deposits lining the walls of arteries thereby affecting blood flow) is accelerated and more extensive in diabetic patients compared with non-diabetics, accounting for approximately 80% of all diabetic mortality. The bottom line is diabetes is destructive to blood vessels and we are confident that the CVProfilorä can provide a new and clinically beneficial piece of information by screening for patients’ cardiovascular health, thereby allowing physicians to better manage this high risk patient population," adds Guettler.

Anita Brinkman, Healthcheck reporter from WPVI TV 6, ABC affiliate in Philadelphia, received her personal CVProfileä during her interview with the company. Brinkman later reported that, "Sixteen million people are afflicted with diabetes and many patients do not keep their diabetes in check. The CVProfilorä measures the flexibility of arteries. The presence of stiff blood vessels is a marker that cardiovascular disease has already started, and doctors can begin treatment before symptoms are observed." Gloria Blakely from the Philadelphia Sun also interviewed the company during the meeting and also received a CVProfileä demonstration.

Further, HDI sponsored a reception during the meeting with Drs. Salafia, Sherif and Raine sharing their clinical experiences regarding the use of the CVProfilorä . Carolyn Salafia, M.D., M.S., is the Director of EarlyPath Clinical and Research Consultation Service in New York, Professor of Pathology and Pediatrics at Columbia University College of Physicians and Surgeons and is an Adjunct Associate Professor of Obstetrics & Gynecology at the New York University School of Medicine. Dr. Salafia utilizes the CVProfilorä to assess patients for the high morbidity and mortality risks to a mother and newborn associated with the onset of preeclampsia. Dr. Salafia emphasized that the CVProfilorä is a low cost, non-invasive, easy-to-use screening tool that may directly measure a major parameter that could be used to possibly allow for earlier intervention in patients with a family history of cardiovascular disease.

Katherine Sherif, M.D., is Director of the Center for Women’s Health & Wellness at the Medical College of Pennsylvania and Co-Director of the Center for Polycystic Ovarian Syndrome. She was named a "Top Doc for Women" in Philadelphia Magazine and recently received the American Association of Medical Colleges Humanism in Medicine Award. Dr. Sherif pointed out that not only does she use the CVProfilorä in her practice at the Women’s Health & Wellness Center, but she also sees clinical application for its use in primary care offices.

Charles H. Raine, III, M.D., is an Adjunct Assistant Professor of Medicine, Department of Medicine, Endocrine Division, at the Medical University of South Carolina; a member of the Editorial Board for the Journal of Ethnicity and Disease; and Director of the Diabetes Control Center in Orangeburg, South Carolina. Dr. Raine commented that diabetes is not solely an endocrine disease, but truly a vascular disease, negatively impacting the blood and oxygen supply to the heart, eyes, feet and legs, kidneys and nerves. He advised physicians to recognize that diabetes is a vascular disease and that the CVProfilorä is an easy-to-use, simple screening tool that can provide a physician with information that he cannot get even with more complex and expensive technology.

About Hypertension Diagnostics, Inc.

Hypertension Diagnostics, Inc. designs, develops, manufactures and markets proprietary cardiovascular profiling systems for clinical and research applications. These systems carry the Underwriters Labs label and the CE Mark of quality, and they are marketed to physicians, other health care professionals and researchers by a direct sales force and via distributors throughout the world. In addition to providing blood pressure values, the systems non-invasively detect subtle changes in the compliance or elasticity of both large and small arteries, which is a unique feature of HDI’s blood pressure waveform analysis technology. The systems include a custom designed Arterial PulseWaveä Sensor to capture waveform data as well as a printer which generates a CVProfileä Report which can assist physicians in their clinical work.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2000 Annual Report on Form 10-KSB, as amended, under the caption "Risk Factors," as well as others not now anticipated.

Hypertension Diagnostics, HDI/PulseWave™ and CVProfilor^® are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Contact: Greg H. Guettler, President